Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
2-aminobenzoic acid-ALRFSKQ-N-(2,4-dinitrophenyl)ethylenediamine + H2O
?
-
-
-
?
2-aminobenzoic acid-KLGFSKQ-N-(2,4-dinitrophenyl)ethylenediamine + H2O
?
-
-
-
?
2-aminobenzoic acid-KLRFSKQ-N-(2,4-dinitrophenyl)ethylenediamine + H2O
?
and analogues
-
-
?
2-aminobenzoic acid-peptidyl-N-(2,4-dinitrophenyl)ethylenediamine + H2O
?
and derivatives, enzyme shows preference for benzyl-Cys or Arg at the P1 position and a hydrophobic non-aromatic residue at position P2
-
-
?
2-aminobenzoyl-LGMISLMKRPQ-N-(2,4-dinitrophenyl)ethylenediamine + H2O
?
benzoyl-FR-4-methylcoumarin 7-amide + H2O
?
benzoyl-His-Arg-7-amido-4-methylcoumarin + H2O
benzoyl-His-Arg + 7-amino-4-methylcoumarin
-
-
-
?
benzoyl-HR-4-methylcoumarin 7-amide + H2O
?
less susceptible substrate
-
-
?
benzoyl-PFR-4-nitroanilide + H2O
?
benzoyl-Phe-Arg-4-methylcoumarin-7-amide + H2O
?
fluorogenic substrates based on the peptide benzoyl-Phe-Arg-4-methylcoumarin-7-amide
-
-
?
benzoyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzoyl-Phe-Arg + 7-amino-4-methylcoumarin
benzoyl-RR-4-methylcoumarin 7-amide + H2O
?
less susceptible substrate
-
-
?
benzoyl-Tyr-Arg-7-amido-4-methylcoumarin + H2O
benzoyl-Tyr-Arg + 7-amino-4-methylcoumarin
-
-
-
?
benzoyl-YR-4-methylcoumarin 7-amide + H2O
?
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
?
Bovine serum albumin + H2O
?
-
-
-
?
Hemoglobin + H2O
?
-
-
-
?
Immunoglobulin G1 + H2O
?
Immunoglobulin G3 + H2O
?
insulin A + H2O
?
-
-
-
?
insulin B + H2O
?
-
-
-
?
N-carbobenzoxy-Arg-Arg-2-(4-methoxy)-naphthylamide + H2O
N-carbobenzoxy-Arg-Arg + 2-amino-4-methoxynaphthalene
-
-
-
?
N-carbobenzoxy-Val-Val-Arg-4-nitroanilide + H2O
?
N-carbobenzoxy-VVR-4-nitroanilide + H2O
N-carbobenzoxy-VVR + 4-nitroaniline
peptidyl-4-nitroanilide + H2O
?
derivatives of
-
-
?
peptidyl-beta-naphthylamide + H2O
?
peptidyl-methylcoumarin amide + H2O
?
and derivatives, enzyme shows preference for benzyl-Cys or Arg at the P1 position and a hydrophobic non-aromatic residue at position P2
-
-
?
additional information
?
-
2-aminobenzoyl-LGMISLMKRPQ-N-(2,4-dinitrophenyl)ethylenediamine + H2O
?
-
-
-
?
2-aminobenzoyl-LGMISLMKRPQ-N-(2,4-dinitrophenyl)ethylenediamine + H2O
?
Abz-LGMISLMKRPQ-EDDnp
-
-
?
azocasein + H2O
?
-
-
-
?
azocasein + H2O
?
-
-
-
-
?
azocasein + H2O
?
-
-
-
?
benzoyl-FR-4-methylcoumarin 7-amide + H2O
?
-
-
-
?
benzoyl-FR-4-methylcoumarin 7-amide + H2O
?
-
-
-
-
?
benzoyl-FR-4-methylcoumarin 7-amide + H2O
?
fluorigenic substrates based on this peptide, substitution of Phe results in less susceptible substrates
-
-
?
benzoyl-PFR-4-nitroanilide + H2O
?
-
-
-
?
benzoyl-PFR-4-nitroanilide + H2O
?
-
-
-
-
?
benzoyl-PFR-4-nitroanilide + H2O
?
-
-
-
?
benzoyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzoyl-Phe-Arg + 7-amino-4-methylcoumarin
-
-
-
?
benzoyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzoyl-Phe-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
benzoyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzoyl-Phe-Arg + 7-amino-4-methylcoumarin
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
?
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
?
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
?
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
?
-
-
-
-
?
benzyloxycarbonyl-Phe-Arg-4-methylcoumarin 7-amide + H2O
?
-
-
-
?
Immunoglobulin G1 + H2O
?
-
-
-
?
Immunoglobulin G1 + H2O
?
cleaves specifically at the hinge region
-
-
?
Immunoglobulin G3 + H2O
?
-
-
-
?
Immunoglobulin G3 + H2O
?
cleaves specifically at the hinge region
-
-
?
KEEASSAVVGGPG + H2O
?
-
-
-
?
KEEASSAVVGGPG + H2O
?
-
-
-
-
?
KEEASSAVVRGPG + H2O
?
-
-
-
?
KEEASSAVVRGPG + H2O
?
-
-
-
-
?
N-carbobenzoxy-Val-Val-Arg-4-nitroanilide + H2O
?
-
-
-
?
N-carbobenzoxy-Val-Val-Arg-4-nitroanilide + H2O
?
excellent substrate
-
-
?
N-carbobenzoxy-VVR-4-nitroanilide + H2O
N-carbobenzoxy-VVR + 4-nitroaniline
-
-
-
?
N-carbobenzoxy-VVR-4-nitroanilide + H2O
N-carbobenzoxy-VVR + 4-nitroaniline
-
-
-
-
?
peptidyl-beta-naphthylamide + H2O
?
derivatives of
-
-
?
peptidyl-beta-naphthylamide + H2O
?
-
derivatives of
-
-
?
additional information
?
-
substrates are chromogenic peptides with a carboxyl Arg or Lys, enzyme requires at least one more amino acid, preferably Arg, Phe, Val or Leu between the terminal Arg or Lys and the amino-blocking group
-
-
?
additional information
?
-
substrates are chromogenic peptides with a carboxyl Arg or Lys, enzyme requires at least one more amino acid, preferably Arg, Phe, Val or Leu between the terminal Arg or Lys and the amino-blocking group
-
-
?
additional information
?
-
-
substrates are chromogenic peptides with a carboxyl Arg or Lys, enzyme requires at least one more amino acid, preferably Arg, Phe, Val or Leu between the terminal Arg or Lys and the amino-blocking group
-
-
?
additional information
?
-
synthetic chromogenic sustrates
-
-
?
additional information
?
-
-
synthetic chromogenic sustrates
-
-
?
additional information
?
-
antigenic character in natural human infections
-
-
?
additional information
?
-
-
antigenic character in natural human infections
-
-
?
additional information
?
-
stimulates potent humoral and cellular immune response during infection in both humans and mice
-
-
?
additional information
?
-
-
stimulates potent humoral and cellular immune response during infection in both humans and mice
-
-
?
additional information
?
-
enzyme plays a role in the production of antibodies against cardiac M2 muscarinic acetylcholine receptor
-
-
?
additional information
?
-
-
enzyme plays a role in the production of antibodies against cardiac M2 muscarinic acetylcholine receptor
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Acquired Immunodeficiency Syndrome
Looking at the proteases from a simple perspective.
Cardiomyopathies
Identification of multiple HLA-A*0201-restricted cruzipain and FL-160 CD8+ epitopes recognized by T cells from chronically Trypanosoma cruzi-infected patients.
Chagas Disease
A cysteine protease inhibitor cures chagas' disease in an immunodeficient-mouse model of infection.
Chagas Disease
A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi.
Chagas Disease
A fragment of the major histocompatibility complex class II-associated p41 invariant chain inhibits cruzipain, the major cysteine proteinase from Trypanosoma cruzi.
Chagas Disease
Angiotensin-converting enzyme limits inflammation elicited by Trypanosoma cruzi cysteine proteases: a peripheral mechanism regulating adaptive immunity via the innate kinin pathway.
Chagas Disease
Anti-trypanosomal activity of non-peptidic nitrile-based cysteine protease inhibitors.
Chagas Disease
Antiprotozoal and cysteine proteases inhibitory activity of dipeptidyl enoates.
Chagas Disease
Apolipoprotein A-I Truncations in Chagas Disease Are Caused by Cruzipain, the Major Cysteine Protease of Trypanosoma cruzi.
Chagas Disease
Application of Computer-Aided Drug Repurposing in the Search of New Cruzipain Inhibitors: Discovery of Amiodarone and Bromocriptine Inhibitory Effects.
Chagas Disease
Assessment of the Cruzain Cysteine Protease Reversible and Irreversible Covalent Inhibition Mechanism.
Chagas Disease
Benzimidazole inhibitors of the major cysteine protease of Trypanosoma brucei.
Chagas Disease
Catalytic Mechanism of Cruzain from Trypanosoma cruzi As Determined from Solvent Kinetic Isotope Effects of Steady-State and Pre-Steady-State Kinetics.
Chagas Disease
Characterisation of Trypanosoma cruzi populations by DNA polymorphism of the cruzipain gene detected by single-stranded DNA conformation polymorphism (SSCP) and direct sequencing.
Chagas Disease
Chemical-biological characterization of a cruzain inhibitor reveals a second target and a mammalian off-target.
Chagas Disease
Chemotherapy of Chagas disease.
Chagas Disease
Coadministration of cruzipain and GM-CSF DNAs, a new immunotherapeutic vaccine against Trypanosoma cruzi infection.
Chagas Disease
Complementarity between a docking and a high-throughput screen in discovering new cruzain inhibitors.
Chagas Disease
Cruzain : the path from target validation to the clinic.
Chagas Disease
Cruzipain Activates Latent TGF-? from Host Cells during T. cruzi Invasion.
Chagas Disease
Cruzipain induces autoantibodies against cardiac muscarinic acetylcholine receptors. Functional and pathological implications.
Chagas Disease
Cruzipain, a major Trypanosoma cruzi antigen, conditions the host immune response in favor of parasite.
Chagas Disease
Cruzipain, the major cysteine protease of Trypanosoma cruzi: a sulfated glycoprotein antigen as relevant candidate for vaccine development and drug target. A review.
Chagas Disease
Cruzipain, the major cysteine proteinase from the protozoan parasite Trypanosoma cruzi.
Chagas Disease
Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi.
Chagas Disease
Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection.
Chagas Disease
Cysteine protease isoforms from Trypanosoma cruzi, cruzipain 2 and cruzain, present different substrate preference and susceptibility to inhibitors.
Chagas Disease
Design, synthesis, and biochemical evaluation of novel cruzain inhibitors with potential application in the treatment of Chagas' disease.
Chagas Disease
Development of a pharmacophore for cruzain using oxadiazoles as virtual molecular probes: quantitative structure-activity relationship studies.
Chagas Disease
Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease.
Chagas Disease
Developments in the treatment of leishmaniasis and trypanosomiasis.
Chagas Disease
Discovery of potent thiosemicarbazone inhibitors of rhodesain and cruzain.
Chagas Disease
Discovery of Potent, Reversible, and Competitive Cruzain Inhibitors with Trypanocidal Activity: A Structure-Based Drug Design Approach.
Chagas Disease
Displacement of the occluding loop by the parasite protein, chagasin, results in efficient inhibition of human cathepsin B.
Chagas Disease
Effects of chlorate on the sulfation process of Trypanosoma cruzi glycoconjugates. Implication of parasite sulfates in cellular invasion.
Chagas Disease
First quantum mechanics/molecular mechanics studies of the inhibition mechanism of cruzain by peptidyl halomethyl ketones.
Chagas Disease
General solid-phase method to prepare novel cyclic ketone inhibitors of the cysteine protease cruzain.
Chagas Disease
Heterologous Chimeric Construct Comprising a Modified Bacterial Superantigen and a Cruzipain Domain Confers Protection Against Trypanosoma cruzi Infection.
Chagas Disease
Host cell invasion by Trypanosoma cruzi is potentiated by activation of bradykinin B(2) receptors.
Chagas Disease
Human T cell responses against the major cysteine proteinase (cruzipain) of Trypanosoma cruzi: role of the multifunctional alpha 2-macroglobulin receptor in antigen presentation by monocytes.
Chagas Disease
Humoral immune response to cruzipain and cardiac dysfunction in chronic Chagas disease.
Chagas Disease
Identification of a new class of nonpeptidic inhibitors of cruzain.
Chagas Disease
Identification of levothyroxine antichagasic activity through computer-aided drug repurposing.
Chagas Disease
Identification of multiple HLA-A*0201-restricted cruzipain and FL-160 CD8+ epitopes recognized by T cells from chronically Trypanosoma cruzi-infected patients.
Chagas Disease
Identification of potent and reversible cruzipain inhibitors for the treatment of Chagas disease.
Chagas Disease
Identification of potent and selective mechanism-based inhibitors of the cysteine protease cruzain using solid-phase parallel synthesis.
Chagas Disease
Identification of Structure-Stabilizing Interactions in Enzymes: A Novel Mechanism to Impact Enzyme Activity.
Chagas Disease
Immune response to a major Trypanosoma cruzi antigen, cruzipain, is differentially modulated in C57BL/6 and BALB/c mice.
Chagas Disease
In vitro and in vivo studies of the trypanocidal properties of WRR-483 against Trypanosoma cruzi.
Chagas Disease
Induction of autophagy increases the proteolytic activity of reservosomes during Trypanosoma cruzi metacyclogenesis.
Chagas Disease
Induction of B- and T-cell responses to cruzipain in the murine model of Trypanosoma cruzi infection.
Chagas Disease
Inhibition of cysteine proteases by a natural biflavone: behavioral evaluation of fukugetin as papain and cruzain inhibitor.
Chagas Disease
Inhibitory effects of human alpha 2-macroglobulin on Trypanosoma cruzi epimastigote proteinases.
Chagas Disease
Investigation of the binding mode of a novel cruzain inhibitor by docking, molecular dynamics, ab initio and MM/PBSA calculations.
Chagas Disease
Leveraging the cruzain S3 subsite to increase affinity for reversible covalent inhibitors.
Chagas Disease
Ligand-induced conformational selection predicts the selectivity of cysteine protease inhibitors.
Chagas Disease
Looking at the proteases from a simple perspective.
Chagas Disease
Major cysteine protease (cruzipain) in Z3 sylvatic isolates of Trypanosoma cruzi from Rio de Janeiro, Brazil.
Chagas Disease
Mapping inhibitor binding modes on an active cysteine protease via nuclear magnetic resonance spectroscopy.
Chagas Disease
Mapping the S1 and S1' subsites of cysteine proteases with new dipeptidyl nitrile inhibitors as trypanocidal agents.
Chagas Disease
Molecular description of ?-keto-based inhibitors of cruzain with activity against Chagas disease combining 3D-QSAR studies and molecular dynamics.
Chagas Disease
Molecular design aided by random forests and synthesis of potent trypanocidal agents as cruzain inhibitors for Chagas disease treatment.
Chagas Disease
Molecular Docking Studies Applied to a Dataset of Cruzain Inhibitors.
Chagas Disease
Molecular dynamics simulations of the free and inhibitor-bound cruzain systems in aqueous solvent: insights on the inhibition mechanism in acidic pH.
Chagas Disease
Molecular Features for Antitrypanosomal Activity of Thiosemicarbazones Revealed by OPS-PLS QSAR Studies.
Chagas Disease
Non-peptidic Cruzain Inhibitors with Trypanocidal Activity Discovered by Virtual Screening and In Vitro Assay.
Chagas Disease
Nonpeptidic tetrafluorophenoxymethyl ketone cruzain inhibitors as promising new leads for Chagas disease chemotherapy.
Chagas Disease
Novel Cruzain Inhibitors for the Treatment of Chagas' Disease.
Chagas Disease
Novel cruzipain inhibitors for the chemotherapy of chronic Chagas disease.
Chagas Disease
On the intrinsic reactivity of highly potent trypanocidal cruzain inhibitors.
Chagas Disease
Oral multicomponent DNA vaccine delivered by attenuated Salmonella elicited immunoprotection against American trypanosomiasis.
Chagas Disease
Overexpression of cruzipain, the major cysteine proteinase of Trypanosoma cruzi, is associated with enhanced metacyclogenesis.
Chagas Disease
Peptidomimetic Vinyl Heterocyclic Inhibitors of Cruzain Effect Antitrypanosomal Activity.
Chagas Disease
Prime-boost immunization with cruzipain co-administered with MALP-2 triggers a protective immune response able to decrease parasite burden and tissue injury in an experimental Trypanosoma cruzi infection model.
Chagas Disease
Proteinases of Trypanosoma cruzi: patential targets for the chemotherapy of Changas desease.
Chagas Disease
Redirection of the immune response to the functional catalytic domain of the cystein proteinase cruzipain improves protective immunity against Trypanosoma cruzi infection.
Chagas Disease
Reversible cysteine protease inhibitors show promise for a chagas disease cure.
Chagas Disease
Specific chemotherapy of Chagas disease: Relevance, current limitations and new approaches.
Chagas Disease
Structural analysis of the N-glycans of the major cysteine proteinase of Trypanosoma cruzi. Identification of sulfated high-mannose type oligosaccharides.
Chagas Disease
Structure-Based Approaches Targeting Parasite Cysteine Proteases.
Chagas Disease
Structure-based design, synthesis and evaluation of conformationally constrained cysteine protease inhibitors.
Chagas Disease
Structure-Based Optimization of Quinazolines as Cruzain and TbrCATL Inhibitors.
Chagas Disease
Sulfates are main targets of immune responses to cruzipain and are involved in heart damage in BALB/c immunized mice.
Chagas Disease
Synthesis of a sugar-based thiosemicarbazone series and structure-activity relationship versus the parasite cysteine proteases: rhodesain, cruzain and Schistosoma mansoni cathepsin B1.
Chagas Disease
Synthesis, Biological Evaluation, and Structure-Activity Relationships of Potent Noncovalent and Nonpeptidic Cruzain Inhibitors as Anti-Trypanosoma cruzi Agents.
Chagas Disease
Tetrafluorophenoxymethyl ketone cruzain inhibitors with improved pharmacokinetic properties as therapeutic leads for Chagas' disease.
Chagas Disease
The crystal structure of cruzain: a therapeutic target for Chagas' disease.
Chagas Disease
The major cysteine proteinase (cruzipain) from Trypanosoma cruzi is antigenic in human infections.
Chagas Disease
The major cysteine proteinase of Trypanosoma cruzi: a valid target for chemotherapy of Chagas disease.
Chagas Disease
The reactivity of sera from chagasic patients against different fragments of cruzipain, the major cysteine proteinase from Trypanosoma cruzi, suggests the presence of defined antigenic and catalytic domains.
Chagas Disease
Trypanosoma cruzi Virulence Factors for the Diagnosis of Chagas' Disease.
Chagas Disease
Understanding Structure-Activity Relationships for Trypanosomal Cysteine Protease Inhibitors by Simulations and Free Energy Calculations.
Chagas Disease
Upregulation of the secretory pathway in cysteine protease inhibitor-resistant Trypanosoma cruzi.
Chagas Disease
[Cruzipain, major cysteine proteinase of Trypanosoma cruzi: sequence and genomic organization of the codifying genes]
Chagas Disease
[The chemotherapy of Chagas disease]
Chagas Disease
[The proliferative response of T cells against cruzipain in chronic chagasic cardiopathy]
Chronic Periodontitis
Design and synthesis of sensitive fluorogenic substrates specific for Lys-gingipain.
Cysticercosis
Characterization of a novel cathepsin L-like protease from Taenia solium metacestodes for the immunodiagnosis of porcine cysticercosis.
Heart Diseases
A striking common O-linked N-acetylglucosaminyl moiety between cruzipain and myosin.
HIV Infections
Cystatin C levels in sera of patients with human immunodeficiency virus infection. A new avidin-biotin ELISA assay for its measurement.
Hypersensitivity
Trypanosoma cruzi: the major cysteinyl proteinase (cruzipain) is a relevant immunogen of parasite acidic antigens (FIII).
Infections
Analysis and partial epitope mapping of human T cell responses to Trypanosoma cruzi cysteinyl proteinase.
Infections
Angiotensin-converting enzyme limits inflammation elicited by Trypanosoma cruzi cysteine proteases: a peripheral mechanism regulating adaptive immunity via the innate kinin pathway.
Infections
Antibody responses to a 33 kDa cysteine protease of Trypanosoma congolense: relationship to 'trypanotolerance' in cattle.
Infections
Coadministration of cruzipain and GM-CSF DNAs, a new immunotherapeutic vaccine against Trypanosoma cruzi infection.
Infections
Congopain from Trypanosoma congolense: drug target and vaccine candidate.
Infections
Cooperative activation of TLR2 and bradykinin B2 receptor is required for induction of type 1 immunity in a mouse model of subcutaneous infection by Trypanosoma cruzi.
Infections
Cruzain and Rhodesain Inhibitors: Last Decade of Advances in Seeking for New Compounds Against American and African Trypanosomiases.
Infections
Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice.
Infections
Cruzipain, a major Trypanosoma cruzi antigen, conditions the host immune response in favor of parasite.
Infections
Cruzipain, a major Trypanosoma cruzi antigen, promotes arginase-2 expression and survival of neonatal mouse cardiomyocytes.
Infections
Cruzipain, the major cysteine proteinase from the protozoan parasite Trypanosoma cruzi.
Infections
Crystal Structures of TbCatB and rhodesain, potential chemotherapeutic targets and major cysteine proteases of Trypanosoma brucei.
Infections
Cystatins up-regulate nitric oxide release from interferon-gamma-activated mouse peritoneal macrophages.
Infections
Detection of cruzipain, the major cysteine proteinase from Trypanosoma cruzi and its C-terminal extension in biological fluids during experimental infection in mice.
Infections
First quantum mechanics/molecular mechanics studies of the inhibition mechanism of cruzain by peptidyl halomethyl ketones.
Infections
Heterologous Chimeric Construct Comprising a Modified Bacterial Superantigen and a Cruzipain Domain Confers Protection Against Trypanosoma cruzi Infection.
Infections
In vitro and in vivo studies of the trypanocidal properties of WRR-483 against Trypanosoma cruzi.
Infections
Induction of antibodies reactive to cardiac myosin and development of heart alterations in cruzipain-immunized mice and their offspring.
Infections
Induction of autophagy increases the proteolytic activity of reservosomes during Trypanosoma cruzi metacyclogenesis.
Infections
Induction of B- and T-cell responses to cruzipain in the murine model of Trypanosoma cruzi infection.
Infections
Induction of NADPH oxidase activity and reactive oxygen species production by a single Trypanosoma cruzi antigen.
Infections
Infection-associated vasculopathy in experimental chagas disease pathogenic roles of endothelin and kinin pathways.
Infections
Interactions between Trypanosoma cruzi Secreted Proteins and Host Cell Signaling Pathways.
Infections
Knockout of the gamma subunit of the AP-1 adaptor complex in the human parasite Trypanosoma cruzi impairs infectivity and differentiation and prevents the maturation and targeting of the major protease cruzipain.
Infections
Looking at the proteases from a simple perspective.
Infections
Oral multicomponent DNA vaccine delivered by attenuated Salmonella elicited immunoprotection against American trypanosomiasis.
Infections
Prime-boost immunization with cruzipain co-administered with MALP-2 triggers a protective immune response able to decrease parasite burden and tissue injury in an experimental Trypanosoma cruzi infection model.
Infections
Proteolytic cleavage of chemokines by Trypanosoma cruzi's cruzipain inhibits chemokine functions by promoting the generation of antagonists.
Infections
Redirection of the immune response to the functional catalytic domain of the cystein proteinase cruzipain improves protective immunity against Trypanosoma cruzi infection.
Infections
RNA Interference of Trypanosoma brucei Cathepsin B and L Affects Disease Progression in a Mouse Model.
Infections
Roles of naturally occurring protease inhibitors in the modulation of host cell signaling and cellular invasion by Trypanosoma cruzi.
Infections
The major cysteine proteinase (cruzipain) from Trypanosoma cruzi is antigenic in human infections.
Infections
The Trypanosoma cruzi protease cruzain mediates immune evasion.
Infections
Trans-sialidase overcomes many antigens to be used as a vaccine candidate against Trypanosoma cruzi.
Infections
Trypanosoma cruzi antigen immunization induces a higher B cell survival in BALB/c mice, a susceptible strain, compared to C57BL/6 B lymphocytes, a resistant strain to cardiac autoimmunity.
Infections
[Analysis of polymorphisms in the trypanothione reductase and cruzipain genes in Colombian strains of Trypanosoma cruzi]
Leishmaniasis, Cutaneous
A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major.
Liver Abscess, Amebic
Circulating antibodies to histolysain, the major cysteine proteinase of Entamoeba histolytica, in amoebic liver abscess patients.
Malaria
Antiprotozoal and cysteine proteases inhibitory activity of dipeptidyl enoates.
Malaria
Discovery and characterization of trypanocidal cysteine protease inhibitors from the 'malaria box'.
Malaria
On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.
Malaria
Structure-Based Approaches Targeting Parasite Cysteine Proteases.
Neoplasm Metastasis
Gold compounds as cysteine protease inhibitors: perspectives for pharmaceutical application as antiparasitic agents.
Neoplasm Metastasis
Looking at the proteases from a simple perspective.
Neoplasms
Blocking the proliferation of human tumor cell lines by peptidase inhibitors from bauhinia seeds.
Neoplasms
In vitro evaluation of the disposition of A novel cysteine protease inhibitor.
Neoplasms
Looking at the proteases from a simple perspective.
Neoplasms
Non-peptidic Cruzain Inhibitors with Trypanocidal Activity Discovered by Virtual Screening and In Vitro Assay.
Neoplasms
Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor.
Parasitemia
Trans-sialidase overcomes many antigens to be used as a vaccine candidate against Trypanosoma cruzi.
Parasitic Diseases
Cruzipain: An Update on its Potential as Chemotherapy Target against the Human Pathogen Trypanosoma cruzi.
Parasitic Diseases
Design, synthesis and biological evaluation of potent azadipeptide nitrile inhibitors and activity-based probes as promising anti-Trypanosoma brucei agents.
Periodontal Diseases
Isolation and characterization of a novel and potent inhibitor of Arg-gingipain from Streptomyces sp. strain FA-70.
Persistent Infection
Cysteine protease isoforms from Trypanosoma cruzi, cruzipain 2 and cruzain, present different substrate preference and susceptibility to inhibitors.
Retinal Degeneration
Cathepsin proteases mediate photoreceptor cell degeneration in Drosophila.
Schistosomiasis
Synthesis of a sugar-based thiosemicarbazone series and structure-activity relationship versus the parasite cysteine proteases: rhodesain, cruzain and Schistosoma mansoni cathepsin B1.
Sparganosis
Differential expression of the 27 kDa cathepsin L-like cysteine protease in developmental stages of Spirometra erinacei.
Starvation
Different signaling pathways are involved in cardiomyocyte survival induced by a Trypanosoma cruzi glycoprotein.
Starvation
Induction of autophagy increases the proteolytic activity of reservosomes during Trypanosoma cruzi metacyclogenesis.
Thrombosis
Looking at the proteases from a simple perspective.
Tick Infestations
Recombinant interferon-gamma promotes immunoglobulin G and cytokine memory responses to cathepsin L-like cysteine proteinase of Hyalomma asiaticum and the efficacy of anti-tick.
Trypanosomiasis
Antibody responses to a 33 kDa cysteine protease of Trypanosoma congolense: relationship to 'trypanotolerance' in cattle.
Trypanosomiasis
Chalcone, acyl hydrazide, and related amides kill cultured Trypanosoma brucei brucei.
Trypanosomiasis, African
2H-1,2,3-Triazole-Based Dipeptidyl Nitriles: Potent, Selective, and Trypanocidal Rhodesain Inhibitors by Structure-Based Design.
Trypanosomiasis, African
Benzimidazole inhibitors of the major cysteine protease of Trypanosoma brucei.
Trypanosomiasis, African
Cruzain and Rhodesain Inhibitors: Last Decade of Advances in Seeking for New Compounds Against American and African Trypanosomiases.
Trypanosomiasis, African
Development of Novel Benzodiazepine-Based Peptidomimetics as Inhibitors of Rhodesain from Trypanosoma brucei rhodesiense.
Trypanosomiasis, African
Developments in the treatment of leishmaniasis and trypanosomiasis.
Trypanosomiasis, African
Drug combination studies of PS-1 and quercetin against rhodesain of Trypanosoma brucei rhodesiense.
Trypanosomiasis, African
Drug Synergism: Studies of Combination of RK-52 and Curcumin against Rhodesain of Trypanosoma brucei rhodesiense.
Trypanosomiasis, African
Fluorovinylsulfones and -Sulfonates as Potent Covalent Reversible Inhibitors of the Trypanosomal Cysteine Protease Rhodesain: Structure-Activity Relationship, Inhibition Mechanism, Metabolism, and In Vivo Studies.
Trypanosomiasis, African
Identification of non-peptidic cysteine reactive fragments as inhibitors of cysteine protease rhodesain.
Trypanosomiasis, African
Inhibition of Rhodesain as a Novel Therapeutic Modality for Human African Trypanosomiasis.
Trypanosomiasis, African
On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.
Trypanosomiasis, African
Optimization of triazine nitriles as rhodesain inhibitors: structure-activity relationships, bioisosteric imidazopyridine nitriles, and X-ray crystal structure analysis with human cathepsin L.
Trypanosomiasis, African
Optimization Strategy of Novel Peptide-Based Michael Acceptors for the Treatment of Human African Trypanosomiasis.
Trypanosomiasis, African
Repurposing a Library of Human Cathepsin L Ligands: Identification of Macrocyclic Lactams as Potent Rhodesain and Trypanosoma brucei Inhibitors.
Trypanosomiasis, African
Screening of acyl hydrazide proteinase inhibitors for antiparasitic activity against Trypanosoma brucei.
Trypanosomiasis, African
Structure, interdomain dynamics, and pH-dependent autoactivation of pro-rhodesain, the main lysosomal cysteine protease from African trypanosomes.
Trypanosomiasis, African
Structure-Based Optimization of Quinazolines as Cruzain and TbrCATL Inhibitors.
Trypanosomiasis, African
Substrate inhibition and allosteric regulation by heparan sulfate of Trypanosoma brucei cathepsin L.
Trypanosomiasis, African
Synthesis of a sugar-based thiosemicarbazone series and structure-activity relationship versus the parasite cysteine proteases: rhodesain, cruzain and Schistosoma mansoni cathepsin B1.
Trypanosomiasis, African
The Inhibition of Cysteine Proteases Rhodesain and TbCatB: a Valuable Approach to Treat Human African Trypanosomiasis.
Trypanosomiasis, African
Understanding Structure-Activity Relationships for Trypanosomal Cysteine Protease Inhibitors by Simulations and Free Energy Calculations.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Alvarez, V.; Parussini, F.; Aslund, L.; Cazzulo, J.J.
Expression in insect cells of active mature cruzipain from Trypanosoma cruzi, containing its C-terminal domain
Protein Expr. Purif.
26
467-475
2002
Trypanosoma cruzi (Q598P5), Trypanosoma cruzi
brenda
Alves, L.C.; Melo, R.L.; Cezari, M.H.S.; Sanderson, S.J.; Mottram, J.C.; Coombs, G.H.; Juliano, L.; Juliano, M.A.
Analysis of the S2 subsite specificities of the recombinant cysteine proteinases CPB of Leishmania mexicana, and cruzain of Trypanosoma cruzi, using fluorescent substrates containing non-natural basic amino acids
Mol. Biochem. Parasitol.
117
137-143
2001
Trypanosoma cruzi (Q598P5), Trypanosoma cruzi
brenda
Cazzulo, J.J.; Bravo, M.; Raimond, A.; Engstroem, U.; Lindeberg, G.; Hellman, U.
Hydrolysis of synthetic peptides by cruzipain, the major cysteine proteinase from Trypanosoma cruzi, provides evidence for self-processing and the possibility of more specific substrates for the enzyme
Cell. Mol. Biol.
42
691-696
1996
Trypanosoma cruzi (Q598P5), Trypanosoma cruzi
brenda
Cazzulo, J.J.; Cazzulo Franke, M.C.; Martinez, J.; Franke de Cazzulo, B.M.
Some kinetic properties of a cysteine proteinase (cruzipain) from Trypanosoma cruzi
Biochim. Biophys. Acta
1037
186-191
1990
Trypanosoma cruzi (Q598P5)
brenda
Cazzulo, J.J.; Stoka, V.; Turk, V.
Cruzipain, the major cysteine proteinase from the protozoan parasite Trypanosoma cruzi
Biol. Chem.
378
1-10
1997
Trypanosoma cruzi (Q598P5), Trypanosoma cruzi
brenda
Del Nery, E.; Juliano, M.A.; Meldal, M.; Svendsen, I.; Scharfstein, J.; Walmsley, A.; Juliano, L.
Characterization of the substrate specificity of the major cysteine protease (cruzipain) from Trypanosoma cruzi using a portion-mixing combinatorial library and fluorogenic peptides
Biochem. J.
323
427-433
1997
Trypanosoma cruzi (Q598P5)
-
brenda
Eakin, A.E.; McGrath, M.E.; McKerrow, J.H.; Fletterick, R.J.; Craik, C.S.
Production of crystallizable cruzain, the major cysteine protease from Trypanosoma cruzi
J. Biol. Chem.
268
6115-6118
1993
Trypanosoma cruzi (Q598P5), Trypanosoma cruzi
brenda
Gillmor, S.A.; Craik, C.S.; Fletterick, R.J.
Structural determinants of specificity in the cysteine protease cruzain
Protein Sci.
6
1603-1611
1997
Trypanosoma cruzi (Q598P5), Trypanosoma cruzi
brenda
Judice, W.A.; Cezari, M.H.; Lima, A.P.; Scharfstein, J.; Chagas, J.R.; Tersariol, I.L.; Juliano, M.A.; Juliano, L.
Comparison of the specificity, stability and individual rate constants with respective activation parameters for the peptidase activity of cruzipain and its recombinant form, cruzain, from Trypanosoma cruzi
Eur. J. Biochem.
268
6578-6586
2001
Trypanosoma cruzi (Q598P5), Trypanosoma cruzi
brenda
Lima, A.P.C.A.; Almeida, P.C.; Tersariol, I.L.S.; Schmitz, V.; Schmaier, A.H.; Juliano, L.; Hirata, I.Y.; Muller-Esterl, W.; Chagas, J.R.; Scharfstein, J.
Heparan sulfate modulates kinin release by Trypanosoma cruzi through the activity of cruzipain
J. Biol. Chem.
277
5875-5881
2002
Trypanosoma cruzi (Q598P5), Trypanosoma cruzi
brenda
McGrath, M.E.; Eakin, A.E.; Engel, J.C.; McKerrow, J.H.; Craik, C.C.; Fletterick, R.J.
The crystal structure of cruzain: a therapeutic target for Chagas' disease
J. Mol. Biol.
247
251-259
1995
Trypanosoma cruzi (Q598P5), Trypanosoma cruzi
brenda
Ramos, A.M.; Duschak, V.G.; Gerez de Burgos, N.M.; Barboza, M.; Remedi, M.S.; Vides, M.A.; Chiabrando, G.A.
Trypanosoma cruzi: cruzipain and membrane-bound cysteine proteinase isoform(s) interacts with human alpha2-macroglobulin and pregnancy zone protein
Exp. Parasitol.
100
121-130
2002
Trypanosoma cruzi (Q598P5), Trypanosoma cruzi
brenda
Salvati, L.; Mattu, M.; Polticelli, F.; Tiberi, F.; Gradoni, L.; Venturini, G.; Bolognesi, M.; Ascenzi, P.
Modulation of the catalytic activity of cruzipain, the major cysteine proteinase from Trypanosoma cruzi, by temperature and pH
Eur. J. Biochem.
268
3253-3258
2001
Trypanosoma cruzi (Q598P5), Trypanosoma cruzi
brenda
Schnapp, A.R.; Eickhoff, C.S.; Sizemore, D.; Curtiss, R.3rd.; Hoft, D.F.
Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice
Infect. Immun.
70
5065-5074
2002
Trypanosoma cruzi (Q598P5), Trypanosoma cruzi
brenda
Sterin-Borda, L.; Giordanengo, L.; Joensen, L.; Gea, S.
Cruzipain induces autoantibodies against cardiac muscarinic acetylcholine receptors. Functional and pathological implications
Eur. J. Immunol.
33
2459-2468
2003
Trypanosoma cruzi (Q598P5), Trypanosoma cruzi
brenda
Stoka, V.; Turk, B.; McKerrow, J.H.; Bjork, I.; Cazzulo, J.J.; Turk, V.
The high stability of cruzipain against pH-induced inactivation is not dependent on its C-terminal domain
FEBS Lett.
469
29-32
2000
Trypanosoma cruzi (Q598P5)
brenda
Cazzulo, J.J.; Martinez, J.; Parodi, A.J.; Wernstedt, C.; Hellman, U.
On the post-translational modifications at the C-terminal domain of the major cysteine proteinase (cruzipain) from Trypanosoma cruzi
FEMS Microbiol. Lett.
79
411-416
1992
Trypanosoma cruzi (Q598P5), Trypanosoma cruzi
brenda
3.4.22.51 cruzipain
more
top
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). 
